BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:32 PM
 | 
Aug 21, 2012
 |  BC Extra  |  Clinical News

Gilead discontinues cicletanine for PAH

Gilead Sciences Inc. (NASDAQ:GILD) discontinued development of cicletanine to treat pulmonary arterial hypertension after the diuretic missed the primary endpoint of improving 6-minute walk distance (6MWD) at 12 weeks vs. placebo in a Phase II trial....

Read the full 165 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >